{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:28:13Z","timestamp":1787772493760,"version":"build-2784847793"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    In patients with acute myeloid leukemia (AML), about 25%\u201335% of patients have a history of other hematological diseases, 10% of patients have a history of malignant tumors in other systems and have received cytotoxic treatment including chemotherapy and\/or radiation, and the disease is categorized as therapy-related acute myeloid leukemia (t-AML) according to the World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues. Two subsets of t-AML are generally recognized based on the nature of prior treatments and the characteristics of the disease. The most common type occurs after exposure to alkylating agents and\/or radiation, with a latent period of 5 to 10 years. The less common type occurs after treatment with agents targeting topoisomerase II and has a shorter latent period of 1 to 5 years. The majority of these cases are associated with balanced recurrent chromosomal translocations frequently involving\n                    <jats:italic toggle=\"yes\">MLL<\/jats:italic>\n                    at 11q23,\n                    <jats:italic toggle=\"yes\">RUNX1<\/jats:italic>\n                    at 21q22, or\n                    <jats:italic toggle=\"yes\">CBFB<\/jats:italic>\n                    at 16q22 and morphologically resemble the features of de novo AML associated with these translocations. Here, we describe a rare case of a 48-year-old female with ovarian cancer who developed AML with\n                    <jats:italic toggle=\"yes\">CBFB\/MYH11<\/jats:italic>\n                    fusion, less than two years after exposure to paclitaxel and carboplatin chemotherapy.\n                  <\/jats:p>","DOI":"10.4103\/ijpm.ijpm_415_22","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T02:40:09Z","timestamp":1717036809000},"page":"865-867","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Therapy-related acute myeloid leukemia with CBFB\/MYH11 in a patient with ovarian cancer after exposure to chemotherapy"],"prefix":"10.4103","volume":"66","author":[{"given":"Xinhong","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Hematology, The Affiliated Hospital of Chengde Medical College Chengde, Hebei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuxia","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Chengde Central Hospital, Chengde, Hebei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongjuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Hospital of Chengde Medical College Chengde, Hebei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pediatric Surgery, The Affiliated Hospital of Chengde Medical College Chengde, Hebei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Hospital of Chengde Medical College Chengde, Hebei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Hospital of Chengde Medical College Chengde, Hebei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Hospital of Chengde Medical College Chengde, Hebei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Hospital of Chengde Medical College Chengde, Hebei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,10,18]]},"reference":[{"key":"R1-20240829","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.23908","article-title":"Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: A report from the Swedish Acute Leukemia Registry","volume":"90","author":"Huleg\u00e5rdh","year":"2015","journal-title":"Am J Hematol"},{"key":"R3-20240829","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1002\/cncr.24367","article-title":"Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia","volume":"115","author":"Borthakur","year":"2009","journal-title":"Cancer"},{"key":"R4-20240829","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0167-4781(98)00139-0","article-title":"Secondary leukemias induced by topoisomerase-targeted drugs","volume":"1400","author":"Felix","year":"1998","journal-title":"Biochim Biophys Acta"},{"key":"R5-20240829","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1182\/blood-2012-04-427039","article-title":"Clonal evolution and devolution after chemotherapy in adult acute myelogenous leukemia","volume":"121","author":"Parkin","year":"2013","journal-title":"Blood"},{"key":"R6-20240829","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/leu.2015.141","article-title":"Somatic mutational landscape of AML with inv (16) or t (8;21) identifies patterns of clonal evolution in relapse leukemia","volume":"30","author":"Sood","year":"2016","journal-title":"Leukemia"},{"key":"R7-20240829","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"R8-20240829","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1182\/bloodadvances.2017015222","article-title":"Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission","volume":"2","author":"Vasu","year":"2018","journal-title":"Blood Adv"},{"key":"R9-20240829","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJM199902043400504","article-title":"Risk of leukemia after platinum-based chemotherapy for ovarian cancer","volume":"340","author":"Travis","year":"1999","journal-title":"N Engl J Med"},{"key":"R10-20240829","article-title":"Paclitaxel induced MDS and AML: A case report and literature review","author":"Bhatnagar","year":"2016","journal-title":"Case Rep Oncol Med 2016"},{"key":"R11-20240829","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0378-5173(01)00986-3","article-title":"Paclitaxel and its formulations","volume":"235","author":"Singla","year":"2002","journal-title":"Int J Pharm"}],"container-title":["Indian Journal of Pathology and Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijpm.ijpm_415_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:49:37Z","timestamp":1787770177000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijpm.ijpm_415_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,18]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijpm.ijpm_415_22","relation":{},"ISSN":["0377-4929","0974-5130"],"issn-type":[{"value":"0377-4929","type":"print"},{"value":"0974-5130","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,18]]},"assertion":[{"value":"2022-05-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}